Table 2 Outcome measures at baseline and 4-month across CG and IG
|  | Control (n = 27) |  | Intervention (n = 29) |  | Group x Time interaction | ||||
|---|---|---|---|---|---|---|---|---|---|
| Â | Baseline | 4-month | p-value | Baseline | 4-month | p-value | B (95% CI) | S.E. | p- value |
Primary Outcomes | |||||||||
KES (kg) | 14.00 (4.36) | 13.52 (4.29) | 0.439 | 15.13 (5.98) | 16.58 (6.25) | 0.189 | 1.63 (-0.73, 3.96) | 1.20 | 0.180 |
MQ | 13.07 (8.15) | 10.28 (7.36) | 0.128 | 17.45 (7.89) | 13.46 (10.05) | 0.005* | -2.20 (-5.64, 1.37) | 1.79 | 0.224 |
Falls efficacy | 25.52 (10.39) | 28.16 (7.69) | 0.125 | 25.38 (10.80) | 30.12 (11.74) | 0.004* | 2.85 (-2.22, 7.99) | 2.60 | 0.279 |
Secondary Outcomes | |||||||||
PPA | 1.48 (1.46) | 1.35 (1.40) | 0.720 | 1.59 (1.96) | 1.16 (1.81) | 0.096 | -0.34 (-0.99, 0.32) | 0.33 | 0.316 |
HGS (kg) | 18.29 (4.37) | 17.59 (4.83) | 0.496 | 18.65 (7.46) | 20.32 (8.58) | 0.127 | 1.38 (-0.25, 3.03) | 0.84 | 0.105 |
6-m fast GS (m/s) | 1.34 (0.38) | 1.36 (0.30) | 0.680 | 1.40 (0.39) | 1.43 (0.34) | 0.879 | 0.01 (-0.09, 0.11) | 0.05 | 0.875 |
TUG (s) | 11.71 (5.88) | 10.58 (2.59) | 0.588 | 12.37 (6.72) | 10.94 (3.28) | 0.217 | -0.88 (-2.71, 1.01) | 0.94 | 0.357 |
30-s sit-to-stand | 14.41 (4.32) | 15.60 (5.80) | 0.389 | 13.75 (3.73) | 14.75 (4.47) | 0.496 | -0.18 (-2.14, 1.76) | 0.99 | 0.859 |
EQ-5D index score | 0.83 (0.09) | 0.85 (0.05) | 0.265 | 0.81 (0.12) | 0.80 (0.11) | 0.955 | -0.03 (-0.08, 0.03) | 0.03 | 0.348 |
GDS | 3.33 (2.54) | 2.96 (2.35) | 0.829 | 4.07 (3.53) | 4.00 (3.39) | 1.00 | 0.22 (-1.30, 1.77) | 0.78 | 0.781 |
Frailty | 1.19 (0.88) | 1.00 (1.00) | 0.723 | 1.52 (0.87) | 1.24 (1.05) | 0.228 | -0.12 (-0.69, 0.46) | 0.29 | 0.684 |